Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

585 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterizing trauma encounters among patients with language other than English preference at a level 1 trauma center's emergency department.
Olakunle OE, Bakdash L, Chai N, Amedi A, Ahuja A, Moran T, Loan P, Smith RN, Yaffee A, Zeidan A. Olakunle OE, et al. Among authors: zeidan a. J Am Coll Emerg Physicians Open. 2024 Jun 5;5(3):e13205. doi: 10.1002/emp2.13205. eCollection 2024 Jun. J Am Coll Emerg Physicians Open. 2024. PMID: 38846103 Free PMC article.
Prognostic impact of 'multi-hit' versus 'single hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.
Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR. Badar T, et al. Among authors: zeidan am. Haematologica. 2024 May 30. doi: 10.3324/haematol.2024.285000. Online ahead of print. Haematologica. 2024. PMID: 38813716 Free article.
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).
Efficace F, Buckstein R, Abel GA, Giesinger JM, Fenaux P, Bewersdorf JP, Brunner AM, Bejar R, Borate U, DeZern AE, Greenberg P, Roboz GJ, Savona MR, Sparano F, Boultwood J, Komrokji R, Sallman DA, Xie Z, Sanz G, Carraway HE, Taylor J, Nimer SD, Della Porta MG, Santini V, Stahl M, Platzbecker U, Sekeres MA, Zeidan AM. Efficace F, et al. Among authors: zeidan am. Hemasphere. 2024 May 21;8(5):e69. doi: 10.1002/hem3.69. eCollection 2024 May. Hemasphere. 2024. PMID: 38774655 Free PMC article. Review.
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg A, Stein E, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Bewersdorf JP, et al. Among authors: zeidan am. Am J Hematol. 2024 May 15. doi: 10.1002/ajh.27366. Online ahead of print. Am J Hematol. 2024. PMID: 38751104 No abstract available.
585 results